Gastroenterology practices sell for 4x to 8x SDE and 7x to 14x EBITDA, measuring earnings before interest, taxes, depreciation, and amortization from procedure fees, ancillary services, management fees, and facility partnerships. Practices with owned or partnered ASCs, ancillary services generating 20%+ of revenue, multiple providers, and established chronic care programs consistently achieve the upper range. The valuation spread reflects procedure volume, asset ownership, revenue diversification, and operational structure that buyers evaluate when pricing gastroenterology acquisitions.

ASC ownership creates the largest structural valuation difference because it captures facility fees, equipment rental revenue, and operating margin alongside physician compensation. Owned or majority-partnered ASCs eliminate facility dependency, provide occupancy cost predictability, and build tangible asset value through facility equity. Facility-dependent practices send 15-25% of total revenue to hospital or independent ASC operators, limiting total economics. Practices with ASC ownership or strong partnerships receiving 10-15% of facility EBITDA add $100,000-300,000 in annual revenue beyond procedure fees. Buyers acquiring owned ASCs value the facility separately using EBITDA multiples of 8x-12x plus working capital, producing higher total transaction values. Property location, regulatory compliance, and facility condition all factor into the ASC valuation component.

Procedure volume and provider diversity determine operational scale and revenue baseline. Practices performing 3,000-5,000 colonoscopies annually with three-plus gastroenterologists demonstrate established market position and efficient operations. Procedure volume growth of 10-15% annually indicates expansion opportunity and competitive advantage. Provider productivity exceeding 1,500 procedures annually per full-time equivalent demonstrates effective scheduling and practice economics. Multi-provider practices reduce owner dependency and support larger patient panels that generate recurring revenue. Single-provider practices require buyer retention of the selling provider or recruitment of replacement providers, reducing effective acquisition value. Buyers evaluate provider employment contracts, non-compete enforceability, and retention probability as critical transaction conditions.

Ancillary services expand revenue beyond procedure fees and create recurring income streams. Pathology services interpreting specimens in-house generate 5-8% additional revenue while supporting quality assurance. Infusion therapy centers serving inflammatory bowel disease and other chronic conditions generate $30,000-50,000 monthly per provider through recurring patient visits and drug administration revenue. Anesthesia services managed internally versus contracted externally capture margin otherwise paid to anesthesia groups. Practices with ancillary services generating 25% of total revenue achieve higher valuations than procedure-only operations because ancillary revenue demonstrates recurring, higher-margin characteristics. Expansion of ancillary services to 20-25% of revenue can increase practice valuation 30-50% by demonstrating diversified economics, comparable to strategies analyzed in our medical practice valuation guide.

Chronic disease patient bases generate predictable, recurring revenue beyond procedure-focused reimbursement. Inflammatory bowel disease patients with established diagnoses generate 8-12 office visits annually plus infusion therapy sessions, creating higher lifetime patient value. Hepatology patient bases with cirrhosis, transplant follow-up, and HCV treatment represent high-value relationships requiring ongoing management. Chronic care management programs billable through CPT codes 99490-99491 generate additional $150-300 monthly revenue per active patient. Practices with 500-plus active chronic disease patients demonstrate revenue stability and growth independent of procedure volume. Established chronic care programs indicate provider reputation, referral network strength, and operational infrastructure supporting advanced patient management.

Payer mix quality determines revenue stability and cash flow. Practices with favorable Medicare reimbursement contracts, commercial payer status at 100%+ of Medicare rates, and minimal self-pay exposure demonstrate revenue security. Medicare colonoscopy reimbursement varies geographically from $400-700 per procedure, creating regional valuation variation. High self-pay or underinsured patient populations reduce effective reimbursement and buyer valuation multiples. Practices with billing efficiency converting 95%+ of charges to collections within 60 days demonstrate strong cash management. Established contracts with major commercial payers at negotiated rates provide predictable revenue. Payer concentration risk with any single payer exceeding 30% of revenue creates dependency that reduces valuation multiples.

Provider retention and operational structure determine post-acquisition independence. Practices with clear provider compensation structures, documented employment agreements, and non-compete enforceability attract buyers seeking stable acquisitions. Multiple providers with competing surgical schedules create operational flexibility for recruitment and retention. Practices with manager-led operations including clinical directors, office managers, and billing leadership function without owner involvement. General management structures reduce buyer integration burden and support faster revenue realization post-acquisition. Owner-dependent practices require buyer involvement in daily operations or recruitment of management replacement, reducing effective acquisition value. Buyer evaluation focuses on management depth and provider contract terms as critical transaction conditions.

Adjusted EBITDA normalizes owner compensation, discretionary entertainment, and above-market supply costs. A practice generating $2M annual procedure revenue with $500K adjusted EBITDA at 10x values at $5M. A comparable practice with owned ASC, ancillary services, and multi-provider structure might command 12x, or $6M—the $1M premium reflects revenue diversification and asset ownership. ASC facility value often adds $2-8M depending on facility size, location, and operating metrics. Real estate ownership of the practice facility adds further value when applicable, similar to valuations discussed in our dental practice valuation guide.

The buyer landscape includes hospital health systems paying 7x-9x EBITDA for practices expanding specialist capabilities, private equity platforms at 8x-12x building regional networks, gastroenterology group practices at 9x-13x consolidating competitors, and ASC operators at 6x-8x acquiring high-volume partners. Hospital systems pay top multiples because acquired practices integrate into existing infrastructure and benefit from patient referral networks and managed care relationships. PE-backed platforms consolidate practices to achieve operational scale and negotiate improved payer contracts across larger networks. Related industries that follow similar consolidation dynamics include Ambulatory Surgery Center (ASC).